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Background: Based on small to moderate effect sizes for the wide range of symptomatic treatments in osteoarthritis
(OA), and on the heterogeneity of OA patients, treatment guidelines for OA have stressed the need for research on
clinical predictors of response to different treatments. A meta-analysis to quantify the effect modified by the
predictors using individual patient data (IPD) is suggested. The initiative to collect and analyze IPD in OA research is
commenced by the OA Trial Bank. The study aims are therefore: to evaluate the efficacy of intra-articular glucocorticoids
for knee or hip OA in specific subgroups of patients with severe pain and (mild) inflammatory signs, over both
short-term and long-term follow-up, using IPD from existing studies; to reach consensus on the rules for cooperation in
a consortium; and to develop and explore the methodological issues of meta-analysis with individual OA patient data.
Methods/Design: For the current IPD analysis we will collect and synthesize IPD from randomized trials studying the
effect of intra-articular glucocorticoid injections in patients with hip or knee OA. Subgroup analyses will be performed for
the primary outcome of pain at both short-term and long-term follow-up, in the subgroups of patients with and
without severe pain and with and without inflammatory signs.
Discussion: This study protocol includes the first study of the OA Trial Bank, an international collaboration that initiates
meta-analyses on predefined subgroups of OA patients from existing literature. This approach ensures a widely
supported initiative and is therefore likely to be successful in data collection of existing trials. The collaboration
developed (that is, the OA Trial Bank) may also lead to future IPD analyses on subgroups of patients with several
intervention strategies applied in OA patients.
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distribution, and reproduction in any medium[1,2]. Identifying responsive subgroups is not simple and
it is essential to use the correct methodology in order
to prevent patients being erroneously deprived of
beneficial treatments, or erroneously assumed to have
an (improved) effect from such treatment. Subgroup-
specific trials are obvious for the different OA joint
groups (for example, hand, hip, knee or foot) and for
treatment specifically aimed at certain OA subgroups
such as osteotomy for varus knee OA [3]. However,
to design trials for every identified subgroup with thed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and unrealistic.
Post hoc analyses within individual trials are frequently
applied to identify subgroups with respect to effect of
treatment. However, these methods of analysis introduce
a high risk of type I and type II errors and are therefore
unreliable [4,5]. A methodologically robust method is to
test for subgroup–treatment interaction effects [3]. This
method carries a much smaller risk of false-positive
results, but large sample sizes are necessary to detect the
effect modification; that is, interaction between sub-
group variable and treatment. A meta-analysis for quan-
tifying interaction effects using individual patient data
(IPD) might overcome the power problem in individual
trials and is therefore considered to be the gold stand-
ard for subgroup analysis [6]. This method requires re-
analysis of IPD made available by the authors of several
trials. In a meta-analysis using IPD, in which the data
from several trials are pooled, the interaction effects be-
tween subgroups and treatment can be reliably assessed
and potential confounders can be adjusted for [6].
The initiative to collect and analyze IPD in OA re-
search is commenced by the OA Trial Bank. The OA
Trial Bank will bring together data from individuals with
OA recruited to different clinical trials from different
countries around the world to form a databank. Poten-
tial subgroups of patients for different interventions in
OA patients will be predefined by the OA Trial Bank
and will be analyzed with IPD.
The first IPD analysis will be performed on the efficacy
of intra-articular (i.a.) glucocorticoid injection. For pa-
tients who are unresponsive to non-invasive treatments
or oral NSAIDs, i.a. glucocorticoid injections can pro-
vide an opportunity to treat OA in the knee or hip.
An i.a. corticosteroid injection is recommended for
OA patients particularly with signs of local inflamma-
tion with joint effusion [2,7-10]. The Cochrane system-
atic review on the effectiveness of i.a. corticosteroid
injection in knee OA found some evidence for the effi-
cacy of i.a. corticosteroid injections compared with i.a.
placebo for pain and patient global assessment at 1
week post injection, with evidence also for continuing
efficacy at 2 and 3 weeks post injection [9]. There are,
however, suggestions that there are subgroups of patients
who do, and do not, respond to i.a. glucocorticoid injec-
tions. A study by Jones and Doherty concluded that the
response to the treatment was not confined to those
patients with clinical evidence of inflammation [11].
Another study did find a greater improvement for pain
among patients with clinical evidence of joint effusion
[12]. Since previous systematic reviews have not consid-
ered IPD, interaction effects between inflammatory signs
and glucocorticoid injections are largely unclear. The
primary aim of this study is therefore to evaluate theefficacy of i.a. glucocorticoids for knee or hip OA in
specific subgroups of patients with severe pain and
(mild) inflammatory signs, over both short-term and
long-term follow-up, using IPD from existing trials. In
addition to the primary aim, we hope to reach consen-
sus on the rules for cooperation in a consortium and to
develop and explore the methodological issues of meta-
analysis with IPD.
Methods/Design
We will carry out an IPD meta-analysis of random-
ized trials studying the effectiveness of i.a. gluco-
corticoid injections in patients with hip or knee OA.
The protocol of this review is not registered in the
PROSPERO database.
Study selection
The following inclusion criteria will be applied for stud-
ies to be included in the OA Trial Bank for the current
study purpose.
Type of studies
All randomized controlled trials, including crossover
studies, evaluating one or more i.a. glucocorticoid prepa-
rations in patients with OA of the knee or hip will be
included. There will be no language restrictions.
Participants
Participants are males and/or females with a diagnosis of
OA of the knee or hip according to published American
College of Rheumatology classification criteria [13,14],
or on the basis of detailed clinical and/or radiographic
information.
Studies including a subgroup of knee or hip OA pa-
tients are also included, as long as IPD are collected.
Types of interventions
All i.a. glucocorticoid preparations used for treatment of
OA of the knee or hip in humans were compared with
control treatments – including placebo (saline, vehicle;
that is, inactive medium in which drugs can be adminis-
tered), i.a. hyaluronan/hylan, other doses of i.a. glucocor-
ticoids, usual conservative treatment (pain medication
and/or exercise therapy) – or were compared with dif-
ferent types of injection procedures of glucocorticoids.
Types of baseline assessments
First, important confounders of severity of pain, age,
gender and body mass index should at least have been
assessed at baseline. Also, if available, signs of inflamma-
tion should be assessed at baseline, either by physical
examination (warmth, effusion) or by additional testing
(ultrasound, magnetic resonance imaging, biopsy, serum
C-reactive protein/erythrocyte sedimentation rate).
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The minimum criterion for inclusion of trials in the
systematic review is adequate reporting of pain. Infor-
mation regarding other outcome measures from the
OMERACT III core set, such as physical function, and
patient global assessment will be analyzed when feas-
ible [15]. The primary outcome measure is pain sever-
ity at short-term (up to 3 weeks) follow-up. There will
be no restrictions regarding duration of follow-up.
Subgroup analyses
Subgroup analyses will be performed for the primary
outcome of pain at both short-term and long-term
follow-up, in the subgroups of patients with and with-
out severe pain and with and without inflammatory
signs. In addition, secondary explorative analyses will
be performed for other subgroups of patients, dependent
on the amount of data available.
Identification of eligible studies
The following databases will be searched from 1995
(based on availability of datasets and authors) until
19 June 2012 for randomized controlled trials of i.a.
glucocorticoid versus control treatment for OA of the knee
or hip: the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE (PubMed), EMBASE, Web of
Science, Scopus, Cinahl, Pedro and the controlled trial reg-
isters. The search strategy is derived from the Cochrane
review on the efficacy of i.a. corticosteroid injections in
knee OA [9]. The detailed search syntax is presented in
Additional file 1: Appendix 1. Reference lists will be hand
searched for further identification of published work. Add-
itional potential ongoing studies are also search by means
of the horizon scanning documents from the UK and the
clinical trial registries.
Two review authors (MvM, SMAB-Z) will independ-
ently first select citations based on titles and abstracts.
Next, full articles are obtained for those citations thought
to fulfill the inclusion criteria and screened by the two
review authors independently. A third review author will
be consulted if consensus is not reached.
Data collection and transfer
All corresponding authors of eligible trials will be
approached and asked to cooperate in this project.
When we cannot reach the corresponding authors, the
institutes in which the trials have been performed will
be contacted. All data deliverers (that is, the research
institutes who own the data) will be asked to sign the
data delivery license agreement, including items on in-
put data, obligations, ownership of data, terms, author-
ship and publications. The coordinator of the OA Trial
Bank will visit the institutes of the data deliverers once;
to collect the data and to sign the license agreement.Datasets will be accepted in any kind of electronic
format (for example, SPSS, Stata, SAS, Excel) or in
paper form, provided that variables and categories are
adequately labeled within the dataset or with a separ-
ate codebook. The original data collection files col-
lected by the coordinator will be kept in their original
version and will be saved on a secured server at the
Erasmus MC Medical University in Rotterdam. To en-
sure the quality of the data, they will be independ-
ently checked for data-entry mistakes and consistency,
and the sum of the individual patient results received
will be compared with the published summary results
from the primary studies. In the case of differences,
authors will be contacted and discrepancies should be
resolved after discussion.
To ensure accurate pooling of data, all items will be
consistently derived from the original databases by the
coordinator of the OA Trial Bank and will consequently
be recoded if necessary. All anonymous data will be
transferred to a secured database at the Erasmus MC
Medical University in Rotterdam. The dataset will not be
used for any other research apart from that described in
the license agreement.
Risk of bias assessment
The methodological quality of all included clinical trials
in the OA Trial Bank will be assessed using the 12 cri-
teria recommended by the Cochrane Collaboration and
will be evaluated independently by two researchers
(Table 1 and Additional file 1: Appendix 2). The criteria
are scored as ‘yes’ (low risk of bias), ‘no’ (high risk of
bias) or ‘unclear’. Any disagreements between the review
authors are resolved by discussion, including input from
a third review author. A study with a low risk of bias is
defined as fulfilling six or more of the criteria items,
which is supported by empirical evidence.
Data extraction
From the published reports, details of the trial design,
interventions and comparator groups will be obtained.
Data on factors used to stratify the study sample will
also be collected (Table 2).
Data obtained from the original databases include
patient characteristics (age, gender, body mass index),
disease-specific characteristics (American College of
Rheumatology criteria, radiographic information, signs
of inflammation, duration of complaints), study charac-
teristics (trial number, types of interventions, doses) and
outcome measures at both baseline and follow-up mea-
surements (pain, function and global perceived recovery).
All randomized patients with a database record will be
entered in the pooled database. All individual trials will
be allocated an individual random trial number. Patients
lost to follow-up or excluded in published per-protocol
Table 2 Input data from individual randomized trials
Type of data
Baseline
At least available input data:
Trial number Created by OA Trial Bank
Patient ID Random number
Date of randomization Date
Age Continuous
Gender Dichotomous (male/female)
Body mass index (or weight and length) Continuous
Type of osteoarthritis Dichotomous (hip/knee)
Type of intervention String variable
Pain severity (VAS, NRS, WOMAC, other) Continuous
Collected for current pilot study:
Signs of inflammation Depends on measurement
method
- physical examination
- imaging (that is, sonography, magnetic
resonance imaging)
- additional testing (ESR, CRP, inflammatory
markers)
Collected when available:
Osteoarthritis characteristics: Depends on measurement
method
- American College of Rheumatology criteria
- Severity
- Radiographic information
- Kellgren and Lawrence score
Duration of complaints Continuous or dichotomous
Physical functioning (WOMAC/KOOS/KSS/…) Continuous
Patient global assessment Continuous or dichotomous
Outcome measures at follow-up
At least available input data:
Pain severity (VAS, NRS, WOMAC, other) Continuous
Collected when available:
Physical functioning (WOMAC/KOOS/KSS/…) Continuous
Patient global assessment Continuous or dichotomous
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; KOOS, Knee injury
and Osteoarthritis Outcome Score ; KSS, Knee Society Score ; NRS, Numerical
Rating Scale ;VAS, Visual Analogue Scale ; WOMAC, Western Ontario and
McMaster Universities Osteoarthritis Index.
Table 1 Sources of risk of bias
Itema Judgment
A) Sequence generation
1. Was the method of randomization adequate? Yes / No /
Unsure
B) Allocation concealment
2. Was the treatment allocation concealed? Yes / No /
Unsure
C) Was knowledge of the allocated interventions
adequately prevented during the study?
3. Was the patient blinded to the intervention? Yes / No /
Unsure
4. Was the care provider blinded to the intervention? Yes / No /
Unsure
5. Was the outcome assessor blinded to the
intervention?
Yes / No /
Unsure
D) Incomplete outcome data
6. Were incomplete outcome data adequately
addressed?
E) Other sources of potential bias
7. Were all randomized participants analyzed in the
group to which they were allocated?
Yes / No /
Unsure
8. Were the groups similar at baseline regarding the
most important prognostic indicators?
Yes / No /
Unsure
9. Were co-interventions avoided or similar? Yes / No /
Unsure
10. Was the compliance acceptable in all groups? Yes / No /
Unsure
11. Was the timing of the outcome assessment
similar in all groups?
Yes / No /
Unsure
aCriteria for a judgment of ‘yes’ for the sources of risk of bias: see Additional
file 1: Appendix 2.
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Trial Bank.
Data analyses
Overall effects between the different comparative treat-
ments and within these comparisons will be estimated in
the pooled IPD. Descriptive comparisons between stud-
ies will be conducted to assess between-study differ-
ences. We assume the data to be missing at random, and
therefore observed patient characteristics will be used to
impute missing data (potential covariates and outcomes)
by means of multiple imputation [16,17]. Missing data
will be imputed within each original study, before data
of the individual studies are pooled. Treatment effects
will be analyzed using a random-effects model. The het-
erogeneity between the separate trials will be tested with
I2 [18]. An additional analysis will be performed by ex-
cluding the trials causing heterogeneity in order to reach
an I2 index <50.
The analyses will be adjusted for variables used in
stratified randomization procedures when necessary.The primary outcome is pain severity at short-term
follow-up. When pain severity is measured on different
scales, we will standardize these pain scores in order to
pool the data. Secondary outcomes include pain severity
assessed at other follow-up durations, physical function-
ing and global assessment [15].
The subgroup factor will, based on consensus, be stan-
dardized to: yes or no severe pain; and yes or no signs of
mild inflammation and yes or no signs of moderate to
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lysis, if possible, will take place for the different assess-
ments to define inflammation, and for hip and knee OA.
One-step approach
A multilevel regression analysis will be applied to esti-
mate the magnitude of the effects in the different sub-
groups with the individuals nested within each study
(permits to include both study-level and patient-level
covariates in the same model). Subgroup analyses will be
performed by including a single covariate in the regression
model to indicate the study in order to adjust for possible
residual confounding by study differences. Other covariates
define possible confounders that can be distributed un-
equally over the treatments in subgroups. Age, gender and
body mass index will be included as a minimum, but if
possible duration of complaints, radiographic severity and
educational level will also be included.
To assess potential subgroup effects, a random-effects
linear regression model will be used to calculate inter-
action effects. The model will include the dependent
variable (that is, pain intensity at follow-up (0 to 100
point scale)), independent variables (that is, treatment
(glucocorticoid injection or control)), the effect modifier
(severe pain (yes or no) and signs of inflammation (yesFigure 1 Flowchart of the OA Trial Bank organization. EULAR, Europea
International; PPI, patient and public involvement.or no)), and an interaction term (pain × treatment or in-
flammation × treatment).
The pooled subgroup effect of glucocorticoid injec-
tions will be estimated according to a mean difference
(for continuous outcomes) and odds ratio (for binary
outcomes) and their 95% confidence intervals, based on
the intention-to-treat principle. Interaction effects with
P <0.05 will be considered statistically significant.
The OA Trial Bank
The described study protocol includes the first study
of the OA Trial Bank, a worldwide collaboration that
initiates meta-analyses on predefined subgroups of OA
patients from existing literature. A chairman, steering
committee and an executive coordinator formalize the
OA Trial Bank (Figure 1). The steering committee guar-
antees continuity of the OA Trial Bank, supervises the
executive coordinator and approves and agrees on all de-
cisions made and methods applied (that is, agrees on the
organizational structure and tasks of all parties involved;
agrees on the design and methods of meta-analyses, def-
inition of subgroups, statistical analyses), provides the
content of the license agreement (data access, transfer
and storage, predefined analyses, confidentiality and reli-
ability statement, authorship) between data deliverersn League Against Rheumatism; OARSI, OsteoArthritis Research Society
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provides safe data storage. The steering committee cur-
rently consists of five internationally acknowledged clinical
and epidemiological researchers in the OA field: a delegate
of the main funder (Dutch Arthritis Foundation), a dele-
gate of OsteoArthritis Research Society International, a
delegate of the European League Against Rheumatism and
two representatives of patient and public involvement
(members of the Arthritis Research UK OA Research Users
Group). The executive coordinator is responsible for the
daily management of the OA Trial Bank, and performs or
supervises the data analyses.
All publications arising from the OA Trial Bank will be
made on behalf of the OA Trial Bank, and (co)authored
(when applicable and following the Vancouver Protocol) by
the data deliverers.
Discussion
The described IPD meta-analysis is necessary to deter-
mine the efficacy of i.a. glucocorticoid injections in sub-
groups of hip and knee OA patients with severe pain
and inflammatory signs. This is the first study that will
combine the data of OA studies within the OA Trial
Bank initiative in order to identify relevant subgroups
for i.a. injection treatment using the IPD of the separate
trials included in the proposed study.
One of the aims of this initiative is to build a solid and
reliable organization for IPD analyses in OA trials; that is,
the OA Trial Bank. The international character of the
steering committee, the multidisciplinary structure, the pa-
tient involvement and the endorsement of OsteoArthritis
Research Society International and the European League
Against Rheumatism will all strengthen this initiative and
hopefully inspire trialists (that is, data deliverers) to join
this initiative. The steering committee ensures that rules of
cooperation are registered and transparent towards data
deliverers. Additionally, methods applied are all approved
by the steering committee. This approach ensures a widely
supported initiative improving the likelihood of successful
data collection for existing trials.
It is intended that the OA Trial Bank initiative will
coordinate future IPD analyses on all essential subgroup
effects for the different intervention strategies applied in
OA patients. The existing trial data on i.a. glucocorticoid
injection will form an ideal starting point for our initia-
tive: there are several recent publications on i.a. gluco-
corticoid injections, but it is not the most frequently
studied intervention. With the experience gained in this
first meta-analysis with IPD, the OA Trial Bank can pilot
their methods and rules for data delivery and analysis in
order to refine subsequent studies on OA subgroup
effects for other frequently studied interventions.
All analyses performed with the IPD collected will be
predefined. Since there are several dangers of observingspurious effects in any subgroup analysis, they should be
predefined and interpreted cautiously. The numbers of
patients included in meta-analyses performed with IPD
afford greater statistical power and might therefore pro-
vide the only context in which it is actually reasonable
to do subgroup analyses [19]. The IPD analysis, taking
the interaction effects between subgroups and treatment
into account, will therefore provide reliably information
on subgroup effects that can be directly implemented in
international guidelines on OA treatments.
Finally, the cooperation and publications of our initia-
tive, apart from the primary outcomes, are likely to give
direction towards other important variables measured –
that is, for both confounders and subgroup variables –
in future randomized trials. International consensus on
variables measured in studies will make it easier for
future meta-analyses with IPD to pool study data and
adjust for potential confounders.
Status of project
Currently, the OA Trial Bank has completed the search
strategies in the different databases, has selected eligible
trials for inclusion and is contacting the corresponding
authors of the trials.
Additional file
Additional file 1: Appendix 1. Search strategy. Appendix 2. Criteria for
a judgement of ‘yes’ for the sources of risk of bias.
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